NcXHF

MENINGIOMA MANAGEMENT
109. Milosevic MF, Frost PJ, Laperriere NJ, et al. Radiotherapy for atypical
or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys.
1996;34:817-822.
110. Miralbell R, Linggood RM, de la Monte S, Convery K, Munzenrider JE,
Mirimanoff RO. The role of radiotherapy in the treatment of subtotally
resected benign meningiomas. J Neurooncol. 1992;13:157-164.
111. Adeberg S, Hartmann C, Welzel T, et al. Long-term outcome after radiotherapy
in patients with atypical and malignant meningiomas: clinical
results in 85 patients treated in a single institution leading to
optimized guidelines for early radiation therapy. Int J Radiat Oncol
Biol Phys. 2012;83:859-864.
112. Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of
atypical meningiomas after gross total resection with or without postoperative
adjuvant radiation. Neurosurgery. 2009;64:56-60 (discussion,
60).
113. Stessin AM, Schwartz A, Judanin G, et al. Does adjuvant external-beam
radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance,
Epidemiology, and End Results (SEER)-based analysis.
J Neurosurg. 2012;117:669-675.
114. Pollock BE, Stafford SL, Link MJ, et al. Stereotactic radiosurgery of
World Health Organization grade II and III intracranial meningiomas:
treatment results on the basis of a 22-year experience. Cancer. 2012;
118:1048-1054.
115. Compter I, Zaugg K, Houben RM, et al. High symptom improvement
and local tumor control using stereotactic radiotherapy when given
early after diagnosis of meningioma: a multicentre study. Strahlenther
Onkol. 2012;188:887-893.
116. Combs SE, Adeberg S, Dittmar JO, et al. Skull base meningiomas: longterm
results and patient self-reported outcome in 507 patients treated
with fractionated stereotactic radiotherapy (FSRT) or intensity modulated
radiotherapy (IMRT). Radiother Oncol. 2013;106:186-191.
117. Duma CM, Lunsford LD, Kondziolka D, et al. Stereotactic radiosurgery
of cavernous sinus meningiomas as an addition or alternative to
microsurgery. Neurosurgery. 1993;32:699-704 (discussion, 704-705).
118. Ganz JC, Schröttner O, Pendl G. Radiation-induced edema after
Gamma Knife treatment for meningiomas. Stereotact Funct Neurosurg.
1996;66 (suppl 1):129-133.
119. Kang CS, Zheng LG, Xu DS. Dose-volume effect in gamma knife radiosurgery
of meningiomas. Stereotact Funct Neurosurg. 1999;73:72-
78.
120. Starke R, Kano H, Ding D, et al. Stereotactic radiosurgery of petroclival
meningiomas: a multicenter study. J Neurooncol. 2014;119:169-176.
121. Sheehan JP, Starke RM, Kano H, et al. Gamma Knife radiosurgery for
sellar and parasellar meningiomas: a multicenter study. J Neurosurg.
2014;120:1268-1277.
122. Soldà F, Wharram B, De Ieso PB, et al. Long-term effıcacy of fractionated
radiotherapy for benign meningiomas. Radiother Oncol. 2013;
109:330-334.
123. Engenhart-Cabillic R, Farhoud A, Sure U, et al. Clinicopathologic features
of aggressive meningioma emphasizing the role of radiotherapy
in treatment. Strahlenther Onkol. 2006;182:641-646.
124. Slater JD, Loredo LN, Chung A, et al. Fractionated proton radiotherapy
for benign cavernous sinus meningiomas. Int J Rad Oncol Biol
Phys. 2012;83:e633-e637.
125. Gudjonsson O, Blomquist E, Nyberg G, et al. Stereotactic irradiation of
skull base meningiomas with high energy protons. Acta neurochir
(Wien). 1999;141:933-940.
126. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent
and progressive atypical and anaplastic meningioma. Neuro Oncol.
2015;17:116-121.
127. Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth
factor A protein level and gene expression in intracranial meningiomas
with brain edema. APMIS. 2011;119:831-843.
128. Preusser M, Hassler M, Birner P, et al. Microvascularization and expression
of VEGF and its receptors in recurring meningiomas: pathobiological
data in favor of anti-angiogenic therapy approaches. Clin
Neuropathol. 2012;31:352-360.
129. Boström JP, Seifert M, Greschus S, et al. Bevacizumab treatment in
malignant meningioma with additional radiation necrosis: an MRI diffusion
and perfusion case study. Strahlenther Onkol. 2014;190:416-
421.
130. Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of
cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol.
2011;22:990-991.
131. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with
recurrent/progressive meningioma: a retrospective series. J Neurooncol.
2012;109:63-70.
132. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas
treated with bevacizumab. J Neurooncol. 2012;109:187-193.
133. Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for
meningiomas in NF2: a retrospective analysis of 15 patients. PloS One.
2013;8:e59941.
134. Puchner MJ, Hans VH, Harati A, et al. Bevacizumab-induced regression
of anaplastic meningioma. Ann Oncol. 2010;21:2445-2446.
135. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebocontrolled
trial of bevacizumab therapy for radiation necrosis of the
central nervous system. Int J Radiat Oncol Biol Phys. 2011;79:1487-
1495.
136. Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of
PTK787/ZK 222584 in recurrent or progressive radiation and surgery
refractory meningiomas. J Neurooncol. 2014;117:93-101.
137. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting
in the antitumor activity of trabectedin. Cancer cell. 2013;23:249-
262.
138. Preusser M, Spiegl-Kreinecker S, Lötsch D, et al. Trabectedin has
promising antineoplastic activity in high-grade meningioma. Cancer.
2012;118:5038-5049.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e115